Searching...
10 results for “pharma strategy”
...Big Pharma's sourcing strategy. And, you know, they have oriented more towards these Chinese molecules mainly because they can get them much cheaper than they can buying comparable molecules from companies in The US or Europe. The other big thing tha
20:22 / 21:27
from transcript20:22 – 21:27
...Pharma kinda almost becomes like the enterprise software industry. Like, at the end of the day, there only are a few companies at scale that have the infrastructure and the go to market to operate. And, like, yes, you can build a big company on top o
1:18:44 / 1:19:48
from transcript1:18:44 – 1:19:48
...pharma together. And some of those will get there through become being pharmas that acquire biotechs, and others will be
24:43 / 25:50
from transcript24:43 – 25:50
...pharma doesn't get it or has their head in the sand. And in fact, I learned this from someone who was in the media industry, and I was always we were talking about disruptive technologies and how these large incumbents always get disrupted. And this
23:57 / 25:10
from transcript23:57 – 25:10
...pharma is increasingly buying their new early stage assets out of China. And so, you know, go back five, six years. The percentage of Big Pharma's acquisitions that were coming from China were single digits.
19:33 / 20:37
from transcript19:33 – 20:37
...pharma. They're not actually biotech isn't a commercialization engine in most cases. There are notable exceptions. Right? But in most cases, you're exiting long before you bring that product to market versus for us. And so you you are always having t
6:43 / 7:45
from transcript6:43 – 7:45
...the pharma value chain as it exists today. I think first off, we should say you basically can't. I'm actually not sure there's a human who can hold all of it in their head, and we won't promise to make this comprehensive. But it is worth knowing a fe
1:19:28 / 1:20:30
from transcript1:19:28 – 1:20:30
...pharma to take an idea or an asset, bring it to a value inflection point. You see some efficacy. You show it's safe. You have a compound. The compound seems like it makes sense, and then sell it to big pharma. They're not actually biotech isn't a com
28:30 / 29:31
from transcript28:30 – 29:31
...order. Pharma spends about $10,000,000,000 a year in direct to consumer marketing today. Direct to the physician is about 7,000,000,000. This is a pretty big shift in terms of where the dollars were going historically, both from within the HCP channe
17:14 / 18:16
from transcript17:14 – 18:16
...and pharma has has been a shrinking, in interest in certain the the rate of growth. What what's it gonna take for these, innovations in in in the science to reflect themselves in in business models and in in growth for the industry? A lot of these bi
22:25 / 23:35
from transcript22:25 – 23:35
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.